Cover Image
Market Research Report

Market Spotlight: Myelodysplastic Syndrome (MDS)

Published by Datamonitor Healthcare Product code 573563
Published Content info 45 Pages
Delivery time: 1-2 business days
Price
Back to Top
Market Spotlight: Myelodysplastic Syndrome (MDS)
Published: March 9, 2018 Content info: 45 Pages
Description

This Market Spotlight report covers the myelodysplastic syndrome market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Approved drugs in the MDS space target DNA methyltransferase, BCR-ABL fusion protein, KIT/c-KIT, platelet-derived growth factor receptor, erythropoietin receptor, angiogenesis, and E3 ubiquitin ligase. The majority of approved therapies are administered via the intravenous route; however, a few products are available in oral and subcutaneous formulations.

Approved drugs in the MDS space target DNA methyltransferase, BCR-ABL fusion protein, KIT/c-KIT, platelet-derived growth factor receptor, erythropoietin receptor, angiogenesis, and E3 ubiquitin ligase. The majority of approved therapies are administered via the intravenous route; however, a few products are available in oral and subcutaneous formulations.

The majority of industry-sponsored drugs in active clinical development for MDS are in Phase II. Therapies in mid- and late-stage development for MDS focus on a wide variety of targets. The pipeline drugs in mid- to late-stage development for MDS are administered via the intravenous, intradermal, oral, subcutaneous, or topical route.

High-impact upcoming events for drugs in the MDS space include topline Phase II trial results. There were 15 licensing and asset acquisition deals agreed during 2013-18. The largest deal during this period was the $935m exclusive licensing agreement in 2014 between Geron Corporation and Janssen Biotech to develop and commercialize Geron Corporation's imetelstat (a telomerase inhibitor) globally for oncology, including hematologic malignancies, and other human therapeutics uses.

Revlimid's sales have ranked highest in the MDS space during 2012-16 and are forecast to remain the highest during the outlook period (2017-22).

The clinical trials distribution across Phases I-IV indicates that the majority of trials for MDS have been in early and mid-phases of development, with 90% of trials in Phase I-II, and only 10% in Phase III-IV.

The US has a substantial lead in the number of MDS clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.

Celgene has the highest number of completed clinical trials for MDS, with 78 completed trials. The company has also carried out the most Phase II trials in MDS, followed by Sanofi, which has sponsored 37 Phase II trials.

Table of Contents
Product Code: DMKC0179850

CONTENTS

5 OVERVIEW

6 KEY TAKEAWAYS

7 DISEASE BACKGROUND

7 Myelodysplastic syndrome subtypes

9 TREATMENT

9 Supportive therapy

9 Growth factors

9 Chemotherapy

10 Stem cell transplant

12 EPIDEMIOLOGY

14 MARKETED DRUGS

16 Approvals by country

19 PIPELINE DRUGS

33 KEY UPCOMING EVENTS

34 LICENSING AND ASSET ACQUISITION DEALS

34 ImmunoGen And Jazz Sign ADC Option Agreement

36 PARENT PATENTS

37 REVENUE OPPORTUNITY

38 CLINICAL TRIAL LANDSCAPE

39 Sponsors by status

40 Sponsors by phase

41 Recent events

42 BIBLIOGRAPHY

42 Prescription information:

44 APPENDIX

LIST OF FIGURES

  • 13 Figure 1: Trends in incident cases of myelodysplastic syndrome, 2016-25
  • 19 Figure 2: Pipeline drugs for myelodysplastic syndrome in the US
  • 20 Figure 3: Pipeline drugs for myelodysplastic syndrome, by company
  • 21 Figure 4: Pipeline drugs for myelodysplastic syndrome, by drug type
  • 21 Figure 5: Pipeline drugs for myelodysplastic syndrome, by classifications
  • 33 Figure 6: Key upcoming events in myelodysplastic syndrome
  • 34 Figure 7: Licensing and asset acquisition deals in myelodysplastic syndrome, 2013-18
  • 36 Figure 8: Parent patents in myelodysplastic syndrome
  • 38 Figure 9: Clinical trials in myelodysplastic syndrome
  • 38 Figure 10: Top 10 drugs for clinical trials in myelodysplastic syndrome
  • 39 Figure 11: Top 10 companies for clinical trials in myelodysplastic syndrome
  • 39 Figure 12: Trial locations in myelodysplastic syndrome
  • 40 Figure 13: Myelodysplastic syndrome trials status
  • 41 Figure 14: Myelodysplastic syndrome trials sponsors, by phase

LIST OF TABLES

  • 12 Table 1: Incident cases of myelodysplastic syndrome, 2016-25
  • 15 Table 2: Marketed drugs for myelodysplastic syndrome
  • 17 Table 3: Approvals by country for myelodysplastic syndrome
  • 23 Table 4: Pipeline drugs for myelodysplastic syndrome in the US
  • 37 Table 5: Historical global sales, by drug ($m), 2012-16
  • 37 Table 6: Forecasted global sales, by drug ($m), 2017-22

 

Back to Top